BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9890487)

  • 1. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
    Koizumi M; Matsumoto S; Takahashi S; Yamashita T; Ogata E
    Clin Nucl Med; 1999 Jan; 24(1):15-20. PubMed ID: 9890487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.
    Blomqvist C; Risteli L; Risteli J; Virkkunen P; Sarna S; Elomaa I
    Br J Cancer; 1996 May; 73(9):1074-9. PubMed ID: 8624266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
    Thomas F; Arriagada R; Spielmann M; Mouriesse H; Le Chevalier T; Fontaine F; Tursz T
    Cancer; 1995 Dec; 76(11):2286-90. PubMed ID: 8635033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.
    Shimozuma K; Sonoo H; Fukunaga M; Ichihara K; Aoyama T; Tanaka K
    Jpn J Clin Oncol; 1999 Jan; 29(1):16-22. PubMed ID: 10073146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
    Bombardieri E; Martinetti A; Miceli R; Mariani L; Castellani MR; Seregni E
    Eur J Nucl Med; 1997 Nov; 24(11):1349-55. PubMed ID: 9371866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
    Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
    Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tc-99m sestamibi scintimammography in the evaluation of response of breast carcinoma to chemotherapy.
    Joaquim AI; Sagarra AJ; Ramos CD; Coudry R; Sagarra RA; Camargo EE
    Clin Nucl Med; 1997 Sep; 22(9):638-40. PubMed ID: 9298303
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
    Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
    Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 12. Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
    Kaufmann P; Dauphine CE; Vargas MP; Burla ML; Isaac NM; Gonzalez KD; Rosing D; Vargas HI
    Am Surg; 2006 Oct; 72(10):935-8. PubMed ID: 17058739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
    Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
    J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast conservation after induction chemotherapy for locally advanced breast cancer.
    Kling KM; Ostrzega N; Schmit P
    Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
    Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
    J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
    Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A
    Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
    Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
    Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic validity of bone metabolic markers for bone metastasis.
    Miura H; Yamamoto I; Takada M; Kigami Y; Ohta T; Yuu I; Hamanaka Y; Matsushita R; Morita R
    Endocr J; 1997 Oct; 44(5):751-7. PubMed ID: 9466334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.